The Research Triangle Park, N.C.-based company posted losses of $882,000, or 0¢ per share, on sales of $4.8 million for the three months ended March 31, seeing losses shrink 94.3¢ while sales grew 145% compared with the same period during the previous year.
Adjusted to exclude one-time items, losses per share were just ahead of the 7¢ consensus on Wall Street, where analysts expected to see sales of $3.8 million, which the company handily topped.
“We continued to generate momentum in the first quarter of 2018, including delivering the second consecutive quarter with multiple Senhance system sales and progressing our U.S. indication expansion strategy. Looking to the balance of 2018, we will continue to leverage the momentum we have generated to drive the global commercial adoption of Senhance,” prez & CEO Todd Pope said in a press release.
Shares in TransEnterix have risen 12.3% so far today, at $2.06 as of 3:09 p.m. EDT.